Patiromer With or Without Food for the Treatment of Hyperkalemia

Phase 4 Completed 114 enrolled Relypsa, Inc.

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of patiromer administered once daily (QD) when given with food compared to without food (experimental treatment group) for the treatment of hyperkalemia (high potassium in the blood).

Timeline

Start: 2016-02
Primary completion: 2016-07
Completion: 2016-08

Publications

Natale P, Palmer SC, Ruospo M, Saglimbene VM, Strippoli GF. Potassium binders for chronic hyperkalaemia in people with chronic kidney disease. Cochrane Database Syst Rev. 2020 Jun 26;6(6):CD013165. doi: 10.1002/14651858.CD013165.pub2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Patiromer	Other / unclassified	8.4 g	Oral

Indications

No indication recorded.